# Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

> **NCT02888743** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 110 (actual)

## Conditions studied

- Metastatic Colorectal Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Colorectal Cancer AJCC v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Durvalumab
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT02888743
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-14
- **Primary completion:** 2023-12-31
- **Final completion:** 2027-01-02
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02888743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02888743, "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02888743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*